Piper Jaffray analyst Charles Duncan, PhD reiterated an Overweight rating and $42 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) saying ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE